Arrowhead Pharmaceuticals (ARWR) Other Non-Current Liabilities (2011 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 13 years of Other Non-Current Liabilities data on file, last reported at $383.8 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 8.96% year-over-year to $383.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $383.8 million (up 8.96% YoY) and the FY2025 annual result came in at $367.4 million, up 7.63% from the prior year.
• Other Non-Current Liabilities advanced to $383.8 million in Q1 2026, from $375.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $383.8 million in Q1 2026 to a low of $669000.0 in Q2 2023.
• A 5-year average of $299.8 million and a median of $338.7 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 50128.85% — and 2025, when it grew 7.21%.
• Tracing ARWR's Other Non-Current Liabilities over 5 years: stood at $252.8 million in 2022, then gained by 8.24% to $273.7 million in 2023, then rose by 26.7% to $346.8 million in 2024, then increased by 8.14% to $375.0 million in 2025, then climbed by 2.36% to $383.8 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $383.8 million (Q1 2026), $375.0 million (Q4 2025), and $367.4 million (Q3 2025), per Business Quant data.